高级检索

低分子肝素钙联合利伐沙班治疗老年晚期肺癌合并肺栓塞的效果研究

谢函君, 邵克武

谢函君, 邵克武. 低分子肝素钙联合利伐沙班治疗老年晚期肺癌合并肺栓塞的效果研究[J]. 实用临床医药杂志, 2020, 24(7): 27-30. DOI: 10.7619/jcmp.202007008
引用本文: 谢函君, 邵克武. 低分子肝素钙联合利伐沙班治疗老年晚期肺癌合并肺栓塞的效果研究[J]. 实用临床医药杂志, 2020, 24(7): 27-30. DOI: 10.7619/jcmp.202007008
shu
XIE Hanjun, SHAO Kewu. Efficiency of low molecular heparin calcium combined with rivaroxaban in the treatment of elderly patients with advanced lung cancer complicated with pulmonary embolism[J]. Journal of Clinical Medicine in Practice, 2020, 24(7): 27-30. DOI: 10.7619/jcmp.202007008
Citation: XIE Hanjun, SHAO Kewu. Efficiency of low molecular heparin calcium combined with rivaroxaban in the treatment of elderly patients with advanced lung cancer complicated with pulmonary embolism[J]. Journal of Clinical Medicine in Practice, 2020, 24(7): 27-30. DOI: 10.7619/jcmp.202007008
shu

低分子肝素钙联合利伐沙班治疗老年晚期肺癌合并肺栓塞的效果研究

  • 湖北省仙桃市中医医院, 1. 内科;

  • 2. 肿瘤科, 湖北 仙桃, 433000

详细信息

  • 中图分类号: R734.2

Efficiency of low molecular heparin calcium combined with rivaroxaban in the treatment of elderly patients with advanced lung cancer complicated with pulmonary embolism

  • 1. Department of Internal Medicine;

  • 2. Department of Oncology, Xiantao Hospital of Traditional Chinese Medicine, Xiantao, Hubei, 433000

摘要

    摘要
  • 摘要: 目的 探讨低分子肝素钙联合利伐沙班治疗老年晚期肺癌合并肺栓塞的临床效果。 方法 选取老年晚期肺癌合并肺栓塞患者84例,采用随机数字表法分为观察组与对照组各42例,对照组采用低分子肝素钙联合华法林治疗,观察组采用低分子肝素钙联合利伐沙班治疗, 2组均连续治疗3个月。比较2组临床疗效、治疗前后血气分析及凝血功能指标、不良反应发生情况。 结果 观察组疾病控制率(DCR)为85.71%, 高于对照组71.43%, 但差异无统计学意义(P>0.05)。治疗后, 2组患者动脉血氧分压［p(O2)］、血氧饱和度(SpO2)水平显著升高(P<0.05), 动脉血二氧化碳分压［p(CO2)］水平显著下降(P<0.05); 观察组治疗后p(O2)、SpO2水平显著高于对照组(P<0.05), p(CO2)水平显著低于对照组(P<0.05)。治疗后, 2组患者纤维蛋白原(FIB)、D-二聚体(D-D)水平显著下降(P<0.05), 凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)值显著升高(P<0.05); 观察组治疗后FIB、D-D水平显著低于对照组(P<0.05), PT、APTT值显著高于对照组(P<0.05)。治疗期间,观察组患者不良反应发生率为9.52%, 低于对照组的19.04%, 但差异无统计学意义(P>0.05)。 结论 低分子肝素钙联合利伐沙班治疗老年晚期肺癌合并肺栓塞疗效显著,能改善患者呼吸功能及凝血功能。
    Abstract: Objective To investigate the clinical efficacy of low molecular heparin calcium combined with rivaroxaban in the treatment of elderly patients with advanced lung cancer complicated with pulmonary embolism. Methods Totally 84 elderly patients with advanced lung cancer complicated with pulmonary embolism were selected and randomly divided into observation group and control group, with 42 cases in each group. The control group was treated with low molecular heparin calcium combined with warfarin, while the observation group was treated with low molecular heparin calcium combined with rivaroxaban. Clinical efficacy, indexes of blood gas analysis and coagulation function before and after treatment, and incidence of adverse reactions were compared between two groups. Results The disease control rate(DCR)of the observation group was 85.71%, which was higher than 71.43% of the control group(P>0.05). After treatment, the arterial oxygen partial pressure ［p(O2)］ and blood oxygen saturation(SpO2)levels significantly increased in both groups(P<0.05), the arterial carbon dioxide partial pressure ［p(CO2)］ level significantly decreased in both groups(P<0.05), and the p(O2)and SpO2 levels in the observation group were significantly higher than the control group(P<0.05), while the p(CO2)level was significantly lower than the control - group(P<0.05). After treatment, the levels of fibrinogen(FIB)and D-dimer(D-D)significantly decreased in both groups(P<0.05), the values of thrombinogen time(PT)and activated partial thromboplastin time(APTT)significantly increased in both groups(P<0.05), and the levels of FIB and D-D in the observation group were significantly lower than the control group(P<0.05), while the values of PT and APTT were significantly higher than the control group(P<0.05). During treatment, the incidence of adverse reactions in the observation group was 9.52%, which was lower than 19.04% in the control group(P>0.05). Conclusion The efficacy of low-molecular heparin calcium combined with rivaroxaban is effective in the treatment of elderly patients with advanced lung cancer complicated with pulmonary embolism, which can improve the respiratory and coagulation functions of patients.
    • HTML全文
    • 参考文献(15)

  • Attarian S, Rahman N, Halmos B. Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance[J]. Ann Transl Med, 2017, 5(18): 377-383.

    Socinski M A, Villaruz L C, Ross J. Understanding mechanisms of resistance in the epithelial growth factor receptor in non-small cell lung cancer and the role of biopsy at progression[J]. Oncologist, 2017, 22(1): 3-11.
    徐昆, 丁宇, 司全金. 利伐沙班对高龄老年急性静脉血栓治疗的有效性和安全性研究[J]. 中华老年多器官疾病杂志, 2016, 15(10): 729-733.
    中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组. 肺血栓栓塞症诊治与预防指南[J]. 中华医学杂志, 2018, 98(14): 1060-1087.
    梁柳丹, 林明宽, 周韶璋, 等. 利伐沙班联合低分肝素钙治疗晚期肺癌合并肺栓塞效果[J]. 中国老年学杂志, 2018, 38(18): 4385-4387.
    唐开华. 肺癌合并肺栓塞危险因素及预后的临床分析[J]. 临床肺科杂志, 2017, 22(8): 1477-1480.

    Mantha S, Laube E, Miao Y M, et al. Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study[J]. J Thromb Thrombolysis, 2017, 43(2): 166-171.
    张春来, 黄炎明, 梁丽萍. 利伐沙班治疗肺栓塞20例临床疗效观察[J]. 中国实用医药, 2016, 11(29): 22-24.

    Lazo-Langner A, Fleet J L, McArthur E, et al. Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study[J]. J Thromb Haemost, 2014, 12(10): 1626-1635.
    柴海强. 利伐沙班联合低分子量肝素治疗急性肺栓塞的临床疗效及其对肺通气功能和血清Xa因子水平的影响[J]. 实用心脑肺血管病杂志, 2018, 26(3): 129-131.
    洪城, 高艺洋, 张萌, 等. 肺腺癌合并肺栓塞患者临床特征分析[J]. 国际呼吸杂志, 2017, 37(18): 1379-1383.

    Choe H K, De Sancho M T, Kim S S, et al. Low molecular weight heparin versus rivaroxaban in the treatment of venous thromboembolism in gastrointestinal malignancies[J]. Blood Coagul Fibrinolysis, 2018, 29(2): 227-230.
    徐执政, 徐静, 郭军, 等. 低分子量肝素联合华法林治疗晚期肺癌合并急性非大面积肺栓塞的临床研究[J]. 健康研究, 2017, 37(1): 38-40.
    张敏霞. 低分子肝素钙联合利伐沙班治疗老年急性肺栓塞的临床疗效[J]. 实用心脑肺血管病杂志, 2018, 26(2): 114-118.
    唐开维, 莫桂清, 潘禹辰. 低分子肝素联合利伐沙班治疗急性肺栓塞的临床疗效[J]. 临床合理用药杂志, 2018, 11(15): 55-56.
    • 相关文章
    • 施引文献(17)

  • 期刊类型引用(16)

    1. 玉鸾. 那屈肝素钙联合利伐沙班治疗肺动脉栓塞患者的临床效果. 中外医学研究. 2025(02): 43-46 . 百度学术
    2. 白洋. 依诺肝素序贯华法林治疗急性肺栓塞的临床效果. 中外医学研究. 2025(04): 45-49 . 百度学术
    3. 王素娥，姚德胜，赵国伟. 老年晚期肺癌患者急性非大面积肺栓塞的影响因素分析. 实用癌症杂志. 2024(01): 90-93 . 百度学术
    4. 张文婷，高媛媛，程诗雨. 通阳宣痹汤加减对晚期肺癌合并(气滞血瘀型)急性非大面积肺栓塞患者预后的影响观察. 四川中医. 2024(02): 100-103 . 百度学术
    5. 潘运昌，卢璐春，林瑞娟，刘吉淡，郑良华. 低分子量肝素钙与利伐沙班联合治疗肺癌合并急性肺栓塞患者的效果. 中外医疗. 2024(01): 12-16 . 百度学术
    6. 王慧，杨燕，崔敏. 利伐沙班联合低分子量肝素钙治疗急性肺栓塞的疗效及对肺通气功能和血浆抗Xa活性水平的影响. 中外医疗. 2024(13): 13-17 . 百度学术
    7. 李洁. 老年急性肺栓塞治疗中应用低分子肝素钙与利伐沙班的疗效. 名医. 2023(10): 153-155 . 百度学术
    8. 彭奇彪. 低分子肝素钠序贯利伐沙班与华法林对急性肺栓塞的治疗效果及炎性因子、凝血功能指标分析. 按摩与康复医学. 2022(08): 19-21 . 百度学术
    9. 杨金方，冯玲，郑海静. 利伐沙班及低分子肝素治疗老年急性肺栓塞患者的效果及其对血流动力学水平及血管内皮功能的影响. 中国医学工程. 2022(06): 67-70 . 百度学术
    10. 陈粟. 低分子肝素钙联合利伐沙班治疗老年晚期肺癌合并肺栓塞的效果观察. 中国实用医药. 2022(21): 22-25 . 百度学术
    11. 魏晓辉，孙海凤，苏智祥，陈文娟. 低分子量肝素钙联合利伐沙班治疗肺癌合并急性肺栓塞的临床疗效及对患者凝血功能和生活质量的影响. 癌症进展. 2022(19): 1966-1969 . 百度学术
    12. 张明明，许新举，屈肖杰. 利伐沙班治疗急性非高危肺血栓栓塞患者的效果及其对血气指标、栓塞程度及血管内皮功能的影响. 中国医学工程. 2021(05): 129-131 . 百度学术
    13. 李春英. 低分子肝素联合华法林抗凝治疗对肺栓塞患者症状缓解情况、血气指标改善情况的影响. 中国医学创新. 2021(22): 81-85 . 百度学术
    14. 张慧. 低分子肝素钙不同时间联用华法林治疗肺栓塞的疗效和用药安全性观察. 中国现代药物应用. 2021(23): 97-99 . 百度学术
    15. 刘会金，时会敏. 低分子肝素钙与利伐沙班治疗急性肺栓塞的临床效果及对D-二聚体水平的影响. 山东第一医科大学(山东省医学科学院)学报. 2021(11): 833-836 . 百度学术
    16. 孙清超，宗亮，张力为. 不同血栓风险评估模型对单孔胸腔镜下肺癌根治术后肺栓塞的术前筛查效果. 血管与腔内血管外科杂志. 2021(07): 851-855 . 百度学术

    其他类型引用(1)

    • 资源附件(0)
计量
  • 文章访问数:  385
  • HTML全文浏览量:  87
  • PDF下载量:  12
  • 被引次数: 17
出版历程
  • 收稿日期:  2020-01-01

目录

摘要
HTML全文
    参考文献(15)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    © 2020 《实用临床医药杂志》编辑部

    地址：江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室邮编：225009电话：0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计